Tobacco consumption concerns with the use of CYP1A2 metabolized antidepressants

American Journal of Psychiatry

Volumn 172, Issue 9, 2015, Pages 909-910

  Gressier, Florence ^a   Rotenberg, Samuel ^a   Ait Tayeb, Abd El Kader ^a   Colle, Romain ^a   Hardy, Patrick ^a   Becquemont, Laurent ^a   Verstuyft, Céline ^a   Corruble, Emmanuelle ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 1A2; DESIPRAMINE; IMIPRAMINE; OXAZEPAM; ZOPICLONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CASE REPORT; CAUCASIAN; CYP1A2 GENE; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAMILTON DEPRESSION RATING SCALE; HUMAN; LETTER; MAJOR DEPRESSION; MIDDLE AGED; PRIORITY JOURNAL; RELAPSE; REMISSION; TOBACCO CONSUMPTION; TOBACCO DEPENDENCE; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; GENETICS; GENOTYPE; HETEROZYGOTE; METABOLISM; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP1A2; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; IMIPRAMINE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; TOBACCO USE DISORDER;

EID: 84941085540     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15010033     Document Type: Letter

References (3)

1. Gunes A, Dahl ML: Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008; 9:625-637
2. Glassman AH, Helzer JE, Covey LS, et al: Smoking, smoking cessation, and major depression. JAMA 1990; 264:1546-1549
3. Sachse C, Brockmöller J, Bauer S, et al: Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47:445-449